|
1
|
Harrison LB, Zelefsky MJ, Pfister DG,
Carper E, Raben A, Kraus DH, Strong EW, Rao A, Thaler H, Polyak T,
et al: Detailed quality of life assessment in patients treated with
primary radiotherapy for squamous cell cancer of the base of the
tongue. Head Neck. 19:169–175. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cooper JS, Fu K, Marks J and Silverman S:
Late effects of radiation therapy in the head and neck region. Int
J Radiat Oncol Biol Phys. 31:1141–1164. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Verastegui EL, Morales RB, Barrera-Franco
JL, Poitevin AC and Hadden J: Long-term immune dysfunction after
radiotherapy to the head and neck area. Int Immunopharmacol.
3:1093–1104. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hockel M, Schlenger K, Aral B, Mitze M,
Schaffer U and Vaupel P: Association between tumor hypoxia and
malignant progression in advanced cancer of the uterine cervix.
Cancer Res. 56:4509–4515. 1996.PubMed/NCBI
|
|
5
|
Chen XY, Wang Z, Li B, Zhang YJ and Li YY:
Pim-3 contributes to radioresistance through regulation of the cell
cycle and DNA damage repair in pancreatic cancer cells. Biochem
Biophys Res Commun. 473:296–302. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wang S, Wang Z, Yang YU, Shi MO and Sun Z:
Overexpression of Ku80 correlates with aggressive
clinicopathological features and adverse prognosis in esophageal
squamous cell carcinoma. Oncol Lett. 10:2705–2712. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Koukourakis MI, Giatromanolaki A,
Danielidis V and Sivridis E: Hypoxia inducible factor (HIf1alpha
and HIF2alpha) and carbonic anhydrase 9 (CA9) expression and
response of head-neck cancer to hypofractionated and accelerated
radiotherapy. Int J Radiat Biol. 84:47–52. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Harrison LB, Chadha M, Hill RJ, Hu K and
Shasha D: Impact of tumor hypoxia and anemia on radiation therapy
outcomes. Oncologist. 7:492–508. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Moeller BJ, Richardson RA and Dewhirst MW:
Hypoxia and radiotherapy: Opportunities for improved outcomes in
cancer treatment. Cancer Metastasis Rev. 26:241–248. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bennett M, Feldmeier J, Smee R and Milross
C: Hyperbaric oxygenation for tumour sensitisation to radiotherapy.
Cochrane Database Syst Rev. 19:CD0050072005.
|
|
11
|
Henke M, Laszig R, Rübe C, Schäfer U,
Haase KD, Schilcher B, Mose S, Beer KT, Burger U, Dougherty C, et
al: Erythropoietin to treat head and neck cancer patients with
anaemia undergoing radiotherapy: Randomised, double-blind,
placebo-controlled trial. Lancet. 362:1255–1260. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Teppo S, Sundquist E, Vered M, Holappa H,
Parkkisenniemi J, Rinaldi T, Lehenkari P, Grenman R, Dayan D,
Risteli J, et al: The hypoxic tumor microenvironment regulates
invasion of aggressive oral carcinoma cells. Exp Cell Res.
319:376–389. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Maxwell PH, Dachs GU, Gleadle JM, Nicholls
LG, Harris AL, Stratford IJ, Hankinson O, Pugh CW and Ratcliffe PJ:
Hypoxia-inducible factor-1 modulates gene expression in solid
tumors and influences both angiogenesis and tumor growth. Proc Natl
Acad Sci USA. 94:8104–8109. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Jing SW, Wang YD, Chen LQ, Sang MX, Zheng
MM, Sun GG, Liu Q, Cheng YJ and Yang CR: Hypoxia suppresses
E-cadherin and enhances matrix metalloproteinase-2 expression
favoring esophageal carcinoma migration and invasion via hypoxia
inducible factor-1 alpha activation. Dis Esophagus. 26:75–83. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Moeller BJ and Dewhirst MW: HIF-1 and
tumour radiosensitivity. Br J Cancer. 95:1–5. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sakai Y, Miwa M, Oe K, Ueha T, Koh A,
Niikura T, Iwakura T, Lee SY, Tanaka M and Kurosaka M: A novel
system for transcutaneous application of carbon dioxide causing an
‘artificial Bohr effect’ in the human body. PLoS One. 6:e241372011.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Takeda D, Hasegawa T, Ueha T, Imai Y,
Sakakibara A, Minoda M, Kawamoto T, Minamikawa T, Shibuya Y, Akisue
T, et al: Transcutaneous carbon dioxide induces mitochondrial
apoptosis and suppresses metastasis of oral squamous cell carcinoma
in vivo. PLoS One. 9:e1005302014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Matsui T, Ota T, Ueda Y, Tanino M and
Odashima S: Isolation of a highly metastatic cell line to lymph
node in human oral squamous cell carcinoma by orthotopic
implantation in nude mice. Oral Oncol. 34:253–256. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Iwata E, Hasegawa T, Takeda D, Ueha T,
Kawamoto T, Akisue T, Sakai Y and Komori T: Transcutaneous carbon
dioxide suppresses epithelial-mesenchymal transition in oral
squamous cell carcinoma. Int J Oncol. 48:1493–1498. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Thomlinson RH and Gray LH: The
histological structure of some human lung cancers and the possible
implications for radiotherapy. Br J Cancer. 9:539–549. 1955.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Brown JM and Wilson WR: Exploiting tumour
hypoxia in cancer treatment. Nat Rev Cancer. 4:437–447. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ryan HE, Poloni M, McNulty W, Elson D,
Gassmann M, Arbeit JM and Johnson RS: Hypoxia-inducible factor-1α
is a positive factor in solid tumor growth. Cancer Res.
60:4010–4015. 2000.PubMed/NCBI
|
|
23
|
Harada H, Itasaka S, Zhu Y, Zeng L, Xie X,
Morinibu A, Shinomiya K and Hiraoka M: Treatment regimen determines
whether an HIF-1 inhibitor enhances or inhibits the effect of
radiation therapy. Br J Cancer. 100:747–757. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Geng L, Donnelly E, McMahon G, Lin PC,
Sierra-Rivera E, Oshinka H and Hallahan DE: Inhibition of vascular
endothelial growth factor receptor signaling leads to reversal of
tumor resistance to radiotherapy. Cancer Res. 61:2413–2419.
2001.PubMed/NCBI
|
|
25
|
Hess C, Vuong V, Hegyi I, Riesterer O,
Wood J, Fabbro D, Glanzmann C, Bodis S and Pruschy M: Effect of
VEGF receptor inhibitor PTK787/ZK222584 [correction of ZK222548]
combined with ionizing radiation on endothelial cells and tumour
growth. Br J Cancer. 85:2010–2016. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kozin SV, Boucher Y, Hicklin DJ, Bohlen P,
Jain RK and Suit HD: Vascular endothelial growth factor
receptor-2-blocking antibody potentiates radiation-induced
long-term control of human tumor xenografts. Cancer Res. 61:39–44.
2001.PubMed/NCBI
|
|
27
|
Lund EL, Bastholm L and Kristjansen PE:
Therapeutic synergy of TNP-470 and ionizing radiation: Effects on
tumor growth, vessel morphology, and angiogenesis in human
glioblastoma multiforme xenografts. Clin Cancer Res. 6:971–978.
2000.PubMed/NCBI
|
|
28
|
Ning S, Laird D, Cherrington JM and Knox
SJ: The antiangiogenic agents SU5416 and SU6668 increase the
antitumor effects of fractionated irradiation. Radiat Res.
157:45–51. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Dunst J, Stadler P, Becker A,
Lautenschläger C, Pelz T, Hänsgen G, Molls M and Kuhnt T: Tumor
volume and tumor hypoxia in head and neck cancers. The amount of
the hypoxic volume is important. Strahlenther Onkol. 179:521–526.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Nordsmark M and Overgaard J: A
confirmatory prognostic study on oxygenation status and
loco-regional control in advanced head and neck squamous cell
carcinoma treated by radiation therapy. Radiother Oncol. 57:39–43.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Stadler P, Becker A, Feldmann HJ, Hänsgen
G, Dunst J, Würschmidt F and Molls M: Influence of the hypoxic
subvolume on the survival of patients with head and neck cancer.
Int J Radiat Oncol Biol Phys. 44:749–754. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Nordsmark M, Overgaard M and Overgaard J:
Pretreatment oxygenation predicts radiation response in advanced
squamous cell carcinoma of the head and neck. Radiother Oncol.
41:31–39. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Nordsmark M, Bentzen SM, Rudat V, Brizel
D, Lartigau E, Stadler P, Becker A, Adam M, Molls M, Dunst J, et
al: Prognostic value of tumor oxygenation in 397 head and neck
tumors after primary radiation therapy. An international
multi-center study. Radiother Oncol. 77:18–24. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Overgaard J and Horsman MR: Modification
of hypoxia-induced radioresistance in tumors by the use of oxygen
and sensitizers. Semin Radiat Oncol. 6:10–21. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Saunders MI, Hoskin PJ, Pigott K, Powell
ME, Goodchild K, Dische S, Denekamp J, Stratford MR, Dennis MF and
Rojas AM: Accelerated radiotherapy, carbogen and nicotinamide
(ARCON) in locally advanced head and neck cancer: A feasibility
study. Radiother Oncol. 45:159–166. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Fan TJ, Han LH, Cong RS and Liang J:
Caspase family proteases and apoptosis. Acta Biochim Biophys Sin
(Shanghai). 37:719–727. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Bosch M, Poulter NS, Vatovec S and
Franklin-Tong VE: Initiation of programmed cell death in
self-incompatibility: Role for cytoskeleton modifications and
several caspase-like activities. Mol Plant. 1:879–887. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kuwana T and Newmeyer DD: Bcl-2-family
proteins and the role of mitochondria in apoptosis. Curr Opin Cell
Biol. 15:691–699. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Sharpe JC, Arnoult D and Youle RJ: Control
of mitochondrial permeability by Bcl-2 family members. Biochim
Biophys Acta. 1644:107–113. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Festjens N, van Gurp M, van Loo G, Saelens
X and Vandenabeele P: Bcl-2 family members as sentinels of cellular
integrity and role of mitochondrial intermembrane space proteins in
apoptotic cell death. Acta Haematol. 111:7–27. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Sagan L: On the origin of mitosing cells.
J Theor Biol. 14:255–274. 1967. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Graeber TG, Osmanian C, Jacks T, Housman
DE, Koch CJ, Lowe SW and Giaccia AJ: Hypoxia-mediated selection of
cells with diminished apoptotic potential in solid tumours. Nature.
379:88–91. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Prasad S, Gupta SC and Tyagi AK: Reactive
oxygen species (ROS) and cancer: Role of antioxidative
nutraceuticals. Cancer Lett. 387:95–105. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Jing L, He MT, Chang Y, Mehta SL, He QP,
Zhang JZ and Li PA: Coenzyme Q10 protects astrocytes from
ROS-induced damage through inhibition of mitochondria-mediated cell
death pathway. Int J Biol Sci. 11:59–66. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Lo YY and Cruz TF: Involvement of reactive
oxygen species in cytokine and growth factor induction of c-fos
expression in chondrocytes. J Biol Chem. 270:11727–11730. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Locksley RM, Killeen N and Lenardo MJ: The
TNF and TNF receptor superfamilies: Integrating mammalian biology.
Cell. 104:487–501. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Chung YM, Lee SB, Kim HJ, Park SH, Kim JJ,
Chung JS and Yoo YD: Replicative senescence induced by
Romo1-derived reactive oxygen species. J Biol Chem.
283:33763–33771. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Kim JJ, Lee SB, Park JK and Yoo YD:
TNF-alpha-induced ROS production triggering apoptosis is directly
linked to Romo1 and Bcl-X(L). Cell Death Differ. 17:1420–1434.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Lee SB, Kim JJ, Kim TW, Kim BS, Lee MS and
Yoo YD: Serum deprivation-induced reactive oxygen species
production is mediated by Romo1. Apoptosis. 15:204–218. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Zheng C, Cotrim AP, Rowzee A, Swaim W,
Sowers A, Mitchell JB and Baum BJ: Prevention of radiation-induced
salivary hypofunction following hKGF gene delivery to murine
submandibular glands. Clin Cancer Res. 17:2842–2851. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Harada K, Ferdous T and Yoshida H:
Investigation of optimal schedule of concurrent radiotherapy with
S-1 for oral squamous cell carcinoma. Oncol Rep. 18:1077–1083.
2007.PubMed/NCBI
|
|
52
|
Chiang IT, Liu YC, Hsu FT, Chien YC, Kao
CH, Lin WJ, Chung JG and Hwang JJ: Curcumin synergistically
enhances the radiosensitivity of human oral squamous cell carcinoma
via suppression of radiation-induced NF-κB activity. Oncol Rep.
31:1729–1737. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Fujii H, Sakata K, Katsumata Y, Sato R,
Kinouchi M, Someya M, Masunaga S, Hareyama M, Swartz HM and Hirata
H: Tissue oxygenation in a murine SCC VII tumor after X-ray
irradiation as determined by EPR spectroscopy. Radiother Oncol.
86:354–360. 2008. View Article : Google Scholar : PubMed/NCBI
|
